Common joint supplement glucosamine linked to 25% faster Alzheimer's progression in new study

Common joint supplement may accelerate Alzheimer's disease progression

New research has found an association between taking glucosamine, a popular over-the-counter supplement used for joint pain, and a higher likelihood of progressing from mild cognitive impairment to Alzheimer's disease. The finding by University of Florida neuroscientists is based on a large retrospective analysis of patients' records as well as supporting data from advanced imaging technology used to scan human brain specimens and Alzheimer's disease mouse models. While the results are preliminary and require validation in a human clinical trial, they provide yet another piece of a much bigger mechanistic picture involving metabolic dysregulation and neurodegeneration, according to the study published today in Nature Metabolism. In the United States, there are about 7 million people living with Alzheimer's and millions more with related dementias such as Lewy body or frontotemporal dementia. A lot of these people actively take an over-the-counter supplement that could be making their disease progression worse." Ramon Sun, Ph.D., senior author, director of the Center for Advanced Spatial Biomolecule Research and associate director for innovation of UF's McKnight Brain Institute As glucosamine is widely available and commonly used by seniors for joint health, researchers set out to investigate whether it could have any effect in Alzheimer's disease and related dementias, known as ADRD. With collaborators Yi Guo, Ph.D., and Jiang Bian, Ph.D., the team used artificial intelligence to comb deidentified UF Health records from 2012 to 2024 for patients diagnosed with either ADRD or mild cognitive impairment, or MCI. They found that a significant proportion - 8% - of both types of patients reported taking glucosamine: 1,896 with ADRD and 2,750 with MCI. After controlling for age, sex and demographics, the analysis showed that glucosamine use was associated with a 25% higher likelihood of progression from mild cognitive impairment to dementia. In addition, researchers found that taking glucosamine was associated with a 25% increase in mortality risk, or the likelihood of death within a specified time frame, among ADRD patients. For the MCI group, there was no such impact, suggesting the impact of glucosamine may be greater in patients with established dementia. Notably, said Sun, researchers revealed that a metabolic process in which a protein and sugar-tagging pathway is overactive in Alzheimer's could be a new target for intervention. "Our results suggest that altered metabolism is a significant contributor to Alzheimer's progression and, in addition, addressing the metabolic defect could be an important complement to approaches focused on Alzheimer's plaques and tangles," Sun said. These new insights were made possible by powerful new spatial technology developed by Sun's lab. "This technology allows us to examine thousands and thousands of molecules created when the body breaks down food or drugs and to uncover intricate pathways that otherwise would stay hidden," Sun said. To peer more deeply into these pathways, the research team focused on glucosamine, a naturally occurring sugar-related molecule that can cross the blood-brain barrier and feed into pathways that build complex sugar structures on proteins. In supplements, it can be made from substances such as shellfish shells or corn. The findings suggest that glucosamine's impact may depend on biological context, with the Alzheimer's brain appearing more vulnerable to this metabolic pathway than the nondiseased brain, said Matt Gentry, Ph.D., chair of UF's Department of Biochemistry and Molecular Biology and a study co-author. "The electronic health record data are very provocative," Gentry said. "While it's an association and not proof of causality, it does raise an important clinical question that now deserves much more attention." In genetically modified mice, the research team showed that glucosamine significantly increased the attachment of sugar residues to proteins in cells. Deficits in "social memory" - or memory of recognition - worsened in glucosamine-treated mice. Conversely, when researchers chemically suppressed this attachment process, memory improved. Then, in collaboration with Stefan Prokop, M.D., the team found significantly increased sugar attachment in Alzheimer's brain specimens from the UF Neuromedicine Brain and Tissue Bank compared with normal controls. Taken together, these results suggest that such metabolic dysfunction is not simply a secondary aspect of Alzheimer's pathology but a contributing driver, they reported. "Proteins are the cell's molecular machines, and many of them need sugar tags added in just the right way to fold correctly, travel to the right place and do their jobs," Gentry said. "What we found in Alzheimer's is that this sugar-tagging system appears to be overactive. The Alzheimer's brain is adding too many of these sugar structures, and this seems to contribute to the disease rather than protect against it." Source: UF Health Journal reference: Hawkinson, T. R., et al. (2026). Hyperglycosylation is a metabolic driver of Alzheimer's disease. Nature Metabolism. DOI: 10.1038/s42255-026-01538-4. https://www.nature.com/articles/s42255-026-01538-4

Glucosamine Supplement Linked to Accelerated Alzheimer's Progression

Summary: A new study uncovered a highly provocative association between glucosamine, a massive over-the-counter joint supplement, and accelerated cognitive decline. The investigation combined artificial intelligence audits of 12 years of electronic health records with post-mortem human brain spatial assays and animal models. The data reveals that glucosamine, which crosses the blood-brain barrier, fuels an already overactive protein "sugar-tagging" pathway in vulnerable brains. This metabolic dysregulation is associated with a 25% higher likelihood of progressing from Mild Cognitive Impairment (MCI) to Alzheimer's disease, alongside a 25% increase in mortality risk for those with established dementia. Key Facts * The Joint Supplement Conundrum: Glucosamine is an exceptionally popular over-the-counter compound routinely taken by millions of seniors to mitigate arthritis and joint pain. Because it easily breaches the blood-brain barrier, it directly interacts with the central nervous system's internal biochemistry. * The 12-Year AI Record Audit: Collaborating investigators utilized artificial intelligence to systematically parse deidentified health records from UF Health spanning 2012 to 2024. The data revealed that an astonishing 8% of all monitored dementia and MCI patients were actively taking glucosamine supplements. * The 25% Dementia Progression Spike: After rigorously controlling for baseline age, biological sex, and patient demographics, the retrospective analysis unmasked that glucosamine consumption is associated with a 25% higher probability of transitioning from mild cognitive impairment to full-blown dementia. * Elevated Mortality in Established ADRD: For patients already living with Alzheimer's Disease and Related Dementias (ADRD), taking glucosamine was linked to a 25% surge in short-term mortality risks. Interestingly, this mortality spike was absent in the MCI group, proving the Alzheimer's brain is uniquely fragile to this metabolic stress. * Overactive Sugar-Tagging Pathology: Using advanced spatial biomolecule technology, senior author Dr. Ramon Sun discovered that the Alzheimer's brain suffers from an overactive protein sugar-tagging pathway. While healthy cells need precision sugar tags to fold proteins properly, the diseased brain adds too many sugar structures, gumming up cellular machinery. * Animal and Post-Mortem Human Validation: * Shifting Past Plaques and Tangles: This discovery firmly frames metabolic dysregulation as a primary, active driver of neurodegeneration rather than a passive, secondary symptom. It establishes a brand-new therapeutic target that complements existing medical strategies focused on amyloid-beta plaques and tau tangles. Source: University of Florida New research has found an association between taking glucosamine, a popular over-the-counter supplement used for joint pain, and a higher likelihood of progressing from mild cognitive impairment to Alzheimer's disease. The finding by University of Florida neuroscientists is based on a large retrospective analysis of patients' records as well as supporting data from advanced imaging technology used to scan human brain specimens and Alzheimer's disease mouse models. While the results are preliminary and require validation in a human clinical trial, they provide yet another piece of a much bigger mechanistic picture involving metabolic dysregulation and neurodegeneration, according to the study published today in Nature Metabolism. "In the United States, there are about 7 million people living with Alzheimer's and millions more with related dementias such as Lewy body or frontotemporal dementia," said senior author Ramon Sun, Ph.D., director of the Center for Advanced Spatial Biomolecule Research and associate director for innovation of UF's McKnight Brain Institute. "A lot of these people actively take an over-the-counter supplement that could be making their disease progression worse." As glucosamine is widely available and commonly used by seniors for joint health, researchers set out to investigate whether it could have any effect in Alzheimer's disease and related dementias, known as ADRD. With collaborators Yi Guo, Ph.D., and Jiang Bian, Ph.D., the team used artificial intelligence to comb deidentified UF Health records from 2012 to 2024 for patients diagnosed with either ADRD or mild cognitive impairment, or MCI. They found that a significant proportion -- 8% -- of both types of patients reported taking glucosamine: 1,896 with ADRD and 2,750 with MCI. After controlling for age, sex and demographics, the analysis showed that glucosamine use was associated with a 25% higher likelihood of progression from mild cognitive impairment to dementia. In addition, researchers found that taking glucosamine was associated with a 25% increase in mortality risk, or the likelihood of death within a specified time frame, among ADRD patients. For the MCI group, there was no such impact, suggesting the impact of glucosamine may be greater in patients with established dementia. Notably, said Sun, researchers revealed that a metabolic process in which a protein and sugar-tagging pathway is overactive in Alzheimer's could be a new target for intervention. "Our results suggest that altered metabolism is a significant contributor to Alzheimer's progression and, in addition, addressing the metabolic defect could be an important complement to approaches focused on Alzheimer's plaques and tangles," Sun said. These new insights were made possible by powerful new spatial technology developed by Sun's lab. "This technology allows us to examine thousands and thousands of molecules created when the body breaks down food or drugs and to uncover intricate pathways that otherwise would stay hidden," Sun said. To peer more deeply into these pathways, the research team focused on glucosamine, a naturally occurring sugar-related molecule that can cross the blood-brain barrier and feed into pathways that build complex sugar structures on proteins. In supplements, it can be made from substances such as shellfish shells or corn. The findings suggest that glucosamine's impact may depend on biological context, with the Alzheimer's brain appearing more vulnerable to this metabolic pathway than the nondiseased brain, said Matt Gentry, Ph.D., chair of UF's Department of Biochemistry and Molecular Biology and a study co-author. "The electronic health record data are very provocative," Gentry said. "While it's an association and not proof of causality, it does raise an important clinical question that now deserves much more attention." In genetically modified mice, the research team showed that glucosamine significantly increased the attachment of sugar residues to proteins in cells. Deficits in "social memory" -- or memory of recognition -- worsened in glucosamine-treated mice. Conversely, when researchers chemically suppressed this attachment process, memory improved. Then, in collaboration with Stefan Prokop, M.D., the team found significantly increased sugar attachment in Alzheimer's brain specimens from the UF Neuromedicine Brain and Tissue Bank compared with normal controls. Taken together, these results suggest that such metabolic dysfunction is not simply a secondary aspect of Alzheimer's pathology but a contributing driver, they reported. "Proteins are the cell's molecular machines, and many of them need sugar tags added in just the right way to fold correctly, travel to the right place and do their jobs," Gentry said. "What we found in Alzheimer's is that this sugar-tagging system appears to be overactive. The Alzheimer's brain is adding too many of these sugar structures, and this seems to contribute to the disease rather than protect against it." Key Questions Answered: Editorial Notes: * This article was edited by a Neuroscience News editor. * Journal paper reviewed in full. * Additional context added by our staff. About this Alzheimer's disease research news Author: Mickie Anderson Source: UF Health Contact: Mickie Anderson - UF Health Image: The image is credited to Neuroscience News Original Research: Open access. "Hyperglycosylation is a metabolic driver of Alzheimer's disease" by Tara R. Hawkinson, Zizhen Liu, Roberto A. Ribas, Terrymar Medina, Rikke S. Nielsen, Harrison A. Clarke, Xin Ma, Angela C. Mueller, Adrielle F. Plasencia, Alexander L. Sheer, Samantha T. Simpson, Charles M. Soto, Jessica Sudderth, Feng Cai, Alex R. Cantrell, Matthieu G. Colpaert, Cameron J. Shedlock, Lei Wu, Lyndsay E. A. Young, Damon D. Kooser, Li Chen, Alison M. Ryan, Sadi Quinones, Jihye Son, Parastoo Azadi, Ralph J. Deberardinis, Stefan Prokop, Derek Allison, Shuang Yang, Hongyu Chen, Yu Huang, Xing He, Kimberly M. Alonge, Jingchuan Guo, Yi Guo, Jiang Bian, Craig W. Vander Kooi, Matthew S. Gentry & Ramon C. Sun. Nature Metabolism DOI:10.1038/s42255-026-01538-4 Abstract Hyperglycosylation is a metabolic driver of Alzheimer's disease Alzheimer's disease (AD) is a devastating neurodegenerative disorder marked by progressive cognitive decline. Metabolic disruptions are widely observed, yet their involvement in the molecular aetiology of AD remains underexplored. Here we identify hyperglycosylation as a driver of AD. Integrating spatial metabolomics, lipidomics and glycomics in transgenic AD mouse models and post-mortem human AD samples, along with advanced spatial isotopic tracing pulse-chase analysis of N-linked glycans, we demonstrate that the conserved phenotype of brain hyperglycosylation is driven by increased glycan biosynthesis. Genetic knockdown of glycan biosynthetic enzymes improves cognitive outcomes in AD mice whereas oral glucosamine supplementation impairs them. A retrospective analysis of electronic health records from patients with AD with varying disease severity shows that glucosamine supplementation is associated with accelerated AD progression and worsened survival. Overall, these results establish hyperglycosylation as a pathological driver of AD and highlight glycan metabolism as an actionable target in the fight against AD.